1
/
of
1
Elabscience
SKU:PKSH034013
Recombinant Human Leukocyte Ig-Like Receptor A3/LILRA3/ILT6/CD85e (C-Fc)
Recombinant Human Leukocyte Ig-Like Receptor A3/LILRA3/ILT6/CD85e (C-Fc)
Regular price
$277.00 USD
Regular price
Sale price
$277.00 USD
Unit price
/
per
Shipping calculated at checkout.
Couldn't load pickup availability
Introducing the Recombinant Human Leukocyte Ig-Like Receptor A3/LILRA3/ILT6/CD85e (C-Fc), a cutting-edge product meticulously designed to cater to the discerning needs of the scientific community. This innovative offering represents a fusion protein that combines the advantageous properties of the Leukocyte Ig-Like Receptor A3 (LILRA3), Interleukin-Like Transcript 6 (ILT6), and Cluster of Differentiation 85e (CD85e) molecules, resulting in a multifaceted solution for various research applications.
Crafted through recombinant technology, this product showcases the utmost precision and quality, ensuring reliable and reproducible results. The fusion of LILRA3, ILT6, and CD85e within a single entity empowers researchers with a comprehensive tool to investigate the intricate mechanisms underlying leukocyte function and immune responses.
The Recombinant Human Leukocyte Ig-Like Receptor A3/LILRA3/ILT6/CD85e (C-Fc) boasts an exquisite structure, meticulously engineered to exhibit optimal binding affinity and stability. This fusion protein is equipped with a C-terminal Fc region, further enhancing its versatility and facilitating downstream applications such as immunoprecipitation, flow cytometry, and functional assays.
With its broad range of potential applications, this product serves as an invaluable asset in elucidating the intricate interplay between leukocyte Ig-like receptors and immune regulation. Researchers can leverage its unique properties to unravel novel insights into immune system modulation, autoimmune diseases, and immunotherapeutic strategies.
In summary, the Recombinant Human Leukocyte Ig-Like Receptor A3/LILRA3/ILT6/CD85e (C-Fc) stands as a pinnacle of scientific innovation, offering a comprehensive and versatile tool for the scientific community. Its fusion of LILRA3, ILT6, and CD85e, coupled with its exceptional binding affinity and stability, empowers researchers to delve deeper into the complexities of leukocyte function and immune responses. Embrace this remarkable product and unlock new frontiers in immunological research.
Crafted through recombinant technology, this product showcases the utmost precision and quality, ensuring reliable and reproducible results. The fusion of LILRA3, ILT6, and CD85e within a single entity empowers researchers with a comprehensive tool to investigate the intricate mechanisms underlying leukocyte function and immune responses.
The Recombinant Human Leukocyte Ig-Like Receptor A3/LILRA3/ILT6/CD85e (C-Fc) boasts an exquisite structure, meticulously engineered to exhibit optimal binding affinity and stability. This fusion protein is equipped with a C-terminal Fc region, further enhancing its versatility and facilitating downstream applications such as immunoprecipitation, flow cytometry, and functional assays.
With its broad range of potential applications, this product serves as an invaluable asset in elucidating the intricate interplay between leukocyte Ig-like receptors and immune regulation. Researchers can leverage its unique properties to unravel novel insights into immune system modulation, autoimmune diseases, and immunotherapeutic strategies.
In summary, the Recombinant Human Leukocyte Ig-Like Receptor A3/LILRA3/ILT6/CD85e (C-Fc) stands as a pinnacle of scientific innovation, offering a comprehensive and versatile tool for the scientific community. Its fusion of LILRA3, ILT6, and CD85e, coupled with its exceptional binding affinity and stability, empowers researchers to delve deeper into the complexities of leukocyte function and immune responses. Embrace this remarkable product and unlock new frontiers in immunological research.
Share
